Incyte Corporation
Traded as NASDAQ: INCY
NASDAQ-100 Component
Industry pharmaceutical company
Founded 1991 (1991)
Headquarters Wilmington, Delaware, United States
Key people
Hervé Hoppenot (President and CEO, 2014)
Revenue ~US$94,500,000 (2011)
~(US$186.5 million) (2011)
Total assets ~US$329 million (2011)
Total equity ~(US$227 million) (2011)
Number of employees
Footnotes / references

Incyte, Corp is an American pharmaceutical company based in Alapocas, Delaware.[3] Incyte has one drug which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to several thousands of patients in the United States, Jakafi.[3] The company was founded in Palo Alto, California in 1991 and went public in 1993.[1]

As of 2014 the company was developing an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly called baricitinib.[4][5] As of August 2016 31 clinical trials had been registered for baricitinib of which 24 had completed,[6] and 4 of 6 phase 3 trials had completed.[7]

As of 2016 epacadostat, an Indoleamine 2,3-dioxygenase (IDO1) inhibitor, is in development for various cancers.[8] The ECHO-202 study (NCT02178722) is evaluating epacadostat in combination with Keytruda® (pembrolizumab)*, Merck’s anti-PD-1 therapy.[9][10]

Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma.[11]


In 2014, Incyte named Hervé Hoppenot president and CEO.[12] Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003.[12]

In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.[13]


  1. 1 2 Scott Goss (2 Mar 2015). "Incyte is Delaware Bio Company of the Year, again". Retrieved 2 Mar 2015.
  2. Incyte Corporation (2012), Form 10-K (SEC filing), Incyte Corporation (published February 22, 2012), Commission File Number: 0-27488, retrieved May 6, 2012
  3. 1 2 Natoli, Cori Anne (May 5, 2012), "Incyte looks to ride on drug's success", The News Journal, retrieved May 6, 2012
  4. "Lilly, Incyte Treatment Shows Positive Results". 9 Dec 2014. Retrieved 2 Mar 2015.
  5. "Baricitinib" (pdf). Statement on a nonproprietary name adopted by the USAN council. American Medical Association.
  6. baricitinib trials
  7. baricitinib phase 3 trials
  8. Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, Madan RA, Heery CR, Hodge JW, Newton R, Schlom J, Tsang KY (2016). "The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells". Oncotarget. doi:10.18632/oncotarget.9326. PMID 27192116.
  9. Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016. July 2016
  10. A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)
  11. "Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development | Business Wire". Retrieved 2015-12-29.
  12. 1 2 "People". Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 41.
  13. "Incyte to Co-Develop Hengrui's SHR-1210 in Up-to-$795M+ Deal". Genetic Engineering & Biotechnology News. 2 September 2015.

External links

This article is issued from Wikipedia - version of the 11/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.